Simply put, the drug maker can no longer count on big price hikes to generate growth. Despite intense scrutiny from Congress and payers, Valeant did raise prices on 16 medicines this year, many of which Maris noted already experienced big price increases in 2015. But going forward, the drug maker will have to rely on doctors writing more prescriptions in order to goose sales.
Read Full Article »
